Skip to main content
. 2021 Jan 7;42(4):648–654. doi: 10.1038/s41401-020-00577-1

Fig. 4. Combination of the DNA-PK inhibitor with osimertinib induces prolonged DNA damage and cell cycle arrest.

Fig. 4

a Western blot analysis of p-DNA-PK (S2056) in H1975-S and H1975-OR cells treated with cisplatin for 24 h. b Western blot analysis of rH2AX in H1975-OR cells treated with NU7441 (4 μM), osimertinib (4 μM), or NU7441 (4 μM) combined with osimertinib (4 μM) for 24 h. c Immunofluorescence analysis of rH2AX in H1975-OR cells treated with NU7441 (4 μM), osimertinib (2 μM), or NU7441 (4 μM) combined with osimertinib (2 μM) for 24 h. d Evaluation of DNA damage by alkaline comet assay in H1975-OR cells treated with NU7441 (4 μM), osimertinib (4 μM), or NU7441 (4 μM) combined with osimertinib (4 μM) for 24 h. e Flow cytometric analysis of the cell cycle in H1975-OR cells treated with NU7441 (4 μM), osimertinib (4 μM), or NU7441 (4 μM) combined with osimertinib (4 μM).